1.14
price down icon0.87%   -0.01
after-market After Hours: 1.14
loading
NanoViricides Inc stock is traded at $1.14, with a volume of 49,688. It is down -0.87% in the last 24 hours and down -4.20% over the past month. NanoViricides, Inc., a nano-biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of viral infections. The company is developing anti-influenza drug candidates at pre-clinical and advanced pre-clinical stage, which include two FluCide drugs, such as NV-INF-2, an oral anti-influenza drug and NV-INF-1, an injectable anti-influenza drug for H7N9, Bird Flu H5N1, and other Highly Pathogenic Influenzas; and HIVCide, an anti-human immunodeficiency virus (HIV) drug candidate that could provide functional cure for HIV/AIDS. It is also developing HerpeCide, a skin cream or gel formulation for the treatment of oral and genital herpes virus infections; and eye drops against viral infections of the external eye, as well as involved in the other research programs against Rabies virus, Ebola, and Marburg viruses. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.
See More
Previous Close:
$1.15
Open:
$1.11
24h Volume:
49,688
Relative Volume:
0.18
Market Cap:
$17.83M
Revenue:
-
Net Income/Loss:
$-8.29M
P/E Ratio:
-1.6286
EPS:
-0.7
Net Cash Flow:
$-6.47M
1W Performance:
-5.79%
1M Performance:
-4.20%
6M Performance:
-19.15%
1Y Performance:
-10.94%
1-Day Range:
Value
$1.11
$1.15
1-Week Range:
Value
$1.11
$1.25
52-Week Range:
Value
$1.0297
$3.59

NanoViricides Inc Stock (NNVC) Company Profile

Name
Name
NanoViricides Inc
Name
Phone
203-937-6137
Name
Address
1 Controls Drive, Shelton, CT
Name
Employee
7
Name
Twitter
@nnvcnyse
Name
Next Earnings Date
2025-02-24
Name
Latest SEC Filings
Name
NNVC's Discussions on Twitter

Compare NNVC with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
NNVC
NanoViricides Inc
1.14 17.83M 0 -8.29M -6.47M -0.70
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.01 124.29B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
610.64 68.39B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
590.06 35.99B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
262.16 33.93B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
264.32 28.47B 3.81B -644.79M -669.77M -6.24

NanoViricides Inc Stock (NNVC) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-11-15 Initiated Midtown Partners Strong Buy

NanoViricides Inc Stock (NNVC) Latest News

pulisher
Mar 31, 2025

Virtu Financial LLC Acquires New Position in NanoViricides, Inc. (NYSE:NNVC) - Defense World

Mar 31, 2025
pulisher
Mar 28, 2025

Small cap wrap: NanoViricides, G Mining Ventures, Nevis Brands... - Proactive Investors

Mar 28, 2025
pulisher
Mar 28, 2025

NanoViricides eyes role in US bird flu fight as USDA unveils $100M initiative - Proactive Investors

Mar 28, 2025
pulisher
Mar 25, 2025

NanoViricides Has Initiated Bio-analytical Studies as Part of IND-Enabling Safety and Toxicology Studies of Lead Candidate NV-HHV-101 - ACCESS Newswire

Mar 25, 2025
pulisher
Mar 15, 2025

NanoViricides (NYSE:NNVC) Trading Up 1.7% – Time to Buy? - Defense World

Mar 15, 2025
pulisher
Mar 12, 2025

Stock Update - Investorsobserver

Mar 12, 2025
pulisher
Mar 11, 2025

AllPennyStocks.com News: Junior Biotech Bounces off $1; Chart Trying to Turn Bullish - ACCESS Newswire

Mar 11, 2025
pulisher
Mar 11, 2025

Market movers: Delta, Kohl's, Asana, NanoViricides... - Proactive Investors UK

Mar 11, 2025
pulisher
Mar 11, 2025

NanoViricides says business unaffected by US tariffs, highlights antiviral pipeline - Proactive financial news

Mar 11, 2025
pulisher
Mar 11, 2025

Nanoviricides Co's Business Not Affected By Tariff Policies Of Us Government Or Corresponding Retaliatory Policies Of Other Governments - Marketscreener.com

Mar 11, 2025
pulisher
Mar 11, 2025

NanoViricides Not Affected by Tariffs and Other Policies, Has Excellent Long Term Outlook, Stock-Price Decline Misguided, Explains the Company - Jonesboro Sun

Mar 11, 2025
pulisher
Mar 08, 2025

Springing into action in time of need: NanoViricides, Inc. (NNVC.OB) - ACCESS Newswire

Mar 08, 2025
pulisher
Mar 04, 2025

Unicycive Therapeutics Inc (NASDAQ:UNCY) stock: Is this a flash in the pan today? - US Post News

Mar 04, 2025
pulisher
Mar 04, 2025

Measles Outbreak: NV-387 Promises To Be An Effective Drug To Treat Patients; We are Ready To Work With HHS, Says NanoViricides President Dr. Anil Diwan - Lelezard

Mar 04, 2025
pulisher
Mar 04, 2025

NanoViricides' NV-387 could provide a crucial missing weapon in the fight against US measles outbreak - Proactive financial news

Mar 04, 2025
pulisher
Mar 04, 2025

Investornewsbreaks Nanoviricides (NYSE American: NNVC) Highlights NV-387 As Potential Measles Treatment Amid Outbreak - MENAFN.COM

Mar 04, 2025
pulisher
Mar 01, 2025

NanoViricides Announces Pricing of $10.2 Million Registered Direct Offering - ACCESS Newswire

Mar 01, 2025
pulisher
Feb 28, 2025

Mpox – a possible US$100mln+ opportunity - Proactive Investors USA

Feb 28, 2025
pulisher
Feb 28, 2025

NanoViricides Successfully Completes Required Genetic Toxicology Testing of Lead Drug Candidate NV-HHV-101 - ACCESS Newswire

Feb 28, 2025
pulisher
Feb 28, 2025

NanoViricides to Provide Corporate Update at the Spartan Capital Investors Conference 2024, Today at 9:45am - ACCESS Newswire

Feb 28, 2025
pulisher
Feb 27, 2025

NanoViricides Has Filed Quarterly Report for Period Ending December 31, 2021Has Sufficient Cash, NV-CoV-2 Coronavirus Drug Candidate Clinical Trials Application Ready - ACCESS Newswire

Feb 27, 2025
pulisher
Feb 27, 2025

NanoViricides Has Filed Quarterly Report for Period Ending March 31, 2020Has Sufficient Cash, Progress on New Coronavirus Drug Program and the Lead HerpeCide(TM) Drug Candidate IND Application - ACCESS Newswire

Feb 27, 2025
pulisher
Feb 27, 2025

NanoViricides Receives Cash Infusion of $2.25 Million - ACCESS Newswire

Feb 27, 2025
pulisher
Feb 27, 2025

NanoViricides Closes on $8.625 Million Underwritten Public Offering of Common Stock - ACCESS Newswire

Feb 27, 2025
pulisher
Feb 27, 2025

NanoViricides Has Initiated Required Safety Pharmacology Assessment of Lead Drug Candidate towards IND - ACCESS Newswire

Feb 27, 2025
pulisher
Feb 21, 2025

Small cap headlines: EnWave, NanoViricides, GoviEx, TNR Gold... - Proactive Investors UK

Feb 21, 2025
pulisher
Feb 19, 2025

NanoViricides targets key milestones in 2025 with NV-387 advancing to Phase II trials - Proactive Investors USA

Feb 19, 2025
pulisher
Feb 19, 2025

NanoViricides, Inc. Has Filed its Quarterly Report - Chronicle-Tribune

Feb 19, 2025
pulisher
Feb 15, 2025

NanoViricides, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2024 - Marketscreener.com

Feb 15, 2025
pulisher
Feb 14, 2025

NanoViricides Inc. (NNVC) reports earnings - Quartz

Feb 14, 2025
pulisher
Feb 14, 2025

NanoViricides: Fiscal Q2 Earnings Snapshot - San Antonio Express-News

Feb 14, 2025
pulisher
Feb 14, 2025

NanoViricides: Fiscal Q2 Earnings Snapshot -February 14, 2025 at 04:38 pm EST - Marketscreener.com

Feb 14, 2025
pulisher
Feb 14, 2025

Is NanoViricides Inc. (NNVC) the Best Nanotech Penny Stock to Invest In? - Insider Monkey

Feb 14, 2025
pulisher
Feb 14, 2025

7 Best Nanotech Penny Stocks to Invest In - Insider Monkey

Feb 14, 2025
pulisher
Feb 11, 2025

NanoViricides announces readiness to combat bird flu with antiviral drug NV-387 - Proactive Investors UK

Feb 11, 2025
pulisher
Feb 11, 2025

NanoViricides Drug Can Fight Bird Flu Pandemic; H5N1 Virus Cannot Escape - Oil City Derrick

Feb 11, 2025
pulisher
Feb 11, 2025

Powerful New Weapon Against Bird Flu: NanoViricides' Drug Outperforms Tamiflu in Lab Tests - StockTitan

Feb 11, 2025
pulisher
Feb 08, 2025

NanoViricides Provides an Update on Its Clinical Program and StrategyNV-387 Could be As Revolutionary as Antibiotics - ACCESS Newswire

Feb 08, 2025
pulisher
Feb 07, 2025

NanoViricides seeks to eliminate treatment delays with its broad spectrum antiviral NV-387 - Proactive Investors UK

Feb 07, 2025
pulisher
Feb 05, 2025

12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga

Feb 05, 2025
pulisher
Feb 05, 2025

NNVC’s price-to-cash ratio: Is it a good investment at the moment? - US Post News

Feb 05, 2025
pulisher
Jan 31, 2025

NanoViricides warns of bird flu pandemic as outbreak spreads in Massachusetts - Proactive Investors USA

Jan 31, 2025
pulisher
Jan 30, 2025

NanoViricides (NYSE:NNVC) Trading Down 1.8% – What’s Next? - Defense World

Jan 30, 2025
pulisher
Jan 29, 2025

NanoViricides to present at MicroCap Conference 2025 in Atlantic City - Proactive Investors Australia

Jan 29, 2025
pulisher
Jan 29, 2025

Game-Changing Antiviral Drug Shows 'Superior Results' Against Multiple Viruses$10B Market Potential - StockTitan

Jan 29, 2025
pulisher
Jan 28, 2025

NanoViricides advances antiviral drug with Phase II Clinical trial to Combat MPox - Proactive Investors USA

Jan 28, 2025

NanoViricides Inc Stock (NNVC) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$67.48
price down icon 1.23%
$73.33
price down icon 0.15%
$31.79
price up icon 1.63%
$18.91
price down icon 7.58%
$92.01
price down icon 1.40%
biotechnology ONC
$264.32
price down icon 3.81%
Cap:     |  Volume (24h):